Cardio-oncology Training in the COVID-19 Era

被引:0
作者
Stephanie Feldman
Jennifer Liu
Richard Steingart
Dipti Gupta
机构
[1] Memorial Sloan-Kettering Cancer Center,Cardiology Division, Department of Medicine
[2] Weill Cornell Medical College,undefined
来源
Current Treatment Options in Oncology | 2021年 / 22卷
关键词
Cardio-oncology; Fellowship training; Medical education; Cardiotoxicity; COVID-19;
D O I
暂无
中图分类号
学科分类号
摘要
Cardio-oncology is a field dedicated to the prevention, diagnosis, and management of cardiovascular disease in cancer patients before, during, and after cancer therapy. It is an emerging field with limited opportunities for structured education and training. In the year 2021, we cannot define the requirements of cardio-oncology training without acknowledging the impact of the global coronavirus disease 19 (COVID-19) pandemic. While this pandemic poses significant health risks to patients with cancer and cardiovascular disease as well as the providers who care for them, it also allows novel opportunities for the nascent field of cardio-oncology to readily adapt. In this article, we detail how the COVID-19 pandemic has impacted all aspects of cardio-oncology training, how programs and trainees can adapt to these challenges, and how lessons learned from the COVID-19 era can continue to positively impact cardio-oncology training for the foreseeable future.
引用
收藏
相关论文
共 173 条
[1]  
Siegel RL(2021)Cancer Statistics, 2021 CA Cancer J Clin 71 7-33
[2]  
Miller KD(2016)Cardio-oncology training: a proposal from the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty J Card Fail 22 465-471
[3]  
Fuchs HE(2017)How to develop a cardio-oncology fellowship Heart Fail Clin 13 361-366
[4]  
Jemal A(2020)Cardio-oncology education and training: JACC Council Perspectives J Am Coll Cardiol 76 2267-2281
[5]  
Lenihan DJ(2020)Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Lancet Oncol 21 335-337
[6]  
Hartlage G(2020)Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Lancet. 395 1054-1062
[7]  
DeCara J(2020)Determinants of COVID-19 disease severity in patients with cancer Nat Med 26 1218-1223
[8]  
Blaes A(2020)Chemotherapy and COVID-19 outcomes in patients with cancer J Clin Oncol 38 3538-3546
[9]  
Finet JE(2020)Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation J Clin Invest 130 6656-6667
[10]  
Lyon AR(2020)Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine N Engl J Med 383 2603-2615